ID   LYN_HUMAN               Reviewed;         512 AA.
AC   P07948; A0AVQ5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 213.
DE   RecName: Full=Tyrosine-protein kinase Lyn;
DE            EC=2.7.10.2;
DE   AltName: Full=Lck/Yes-related novel protein tyrosine kinase;
DE   AltName: Full=V-yes-1 Yamaguchi sarcoma viral related oncogene homolog;
DE   AltName: Full=p53Lyn;
DE   AltName: Full=p56Lyn;
GN   Name=LYN; Synonyms=JTK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=3561390; DOI=10.1128/MCB.7.1.237;
RA   Yamanashi Y., Fukushige S., Semba K., Sukegawa J., Miyajima N.,
RA   Matsubara K., Yamamoto T., Toyoshima K.;
RT   "The yes-related cellular gene lyn encodes a possible tyrosine kinase
RT   similar to p56lck.";
RL   Mol. Cell. Biol. 7:237-243(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=8125304; DOI=10.1016/0378-1119(94)90811-7;
RA   Rider L.G., Raben N., Miller L., Jelsema C.;
RT   "The cDNAs encoding two forms of the LYN protein tyrosine kinase are
RT   expressed in rat mast cells and human myeloid cells.";
RL   Gene 138:219-222(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-424.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-424.
RX   PubMed=1510669; DOI=10.1016/S0006-291X(05)81562-1;
RA   Bielke W., Ziemiecki A., Kappos L., Miescher G.C.;
RT   "Expression of the B cell-associated tyrosine kinase gene Lyn in
RT   primary neuroblastoma tumours and its modulation during the
RT   differentiation of neuroblastoma cell lines.";
RL   Biochem. Biophys. Res. Commun. 186:1403-1409(1992).
RN   [6]
RP   FUNCTION IN CD19 PHOSPHORYLATION, AND INTERACTION WITH CD19.
RX   PubMed=7687428; DOI=10.1006/bbrc.1993.1807;
RA   Roifman C.M., Ke S.;
RT   "CD19 is a substrate of the antigen receptor-associated protein
RT   tyrosine kinase in human B cells.";
RL   Biochem. Biophys. Res. Commun. 194:222-225(1993).
RN   [7]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND INTERACTION WITH HCLS1.
RX   PubMed=7682714; DOI=10.1073/pnas.90.8.3631;
RA   Yamanashi Y., Okada M., Semba T., Yamori T., Umemori H., Tsunasawa S.,
RA   Toyoshima K., Kitamura D., Watanabe T., Yamamoto T.;
RT   "Identification of HS1 protein as a major substrate of protein-
RT   tyrosine kinase(s) upon B-cell antigen receptor-mediated signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:3631-3635(1993).
RN   [8]
RP   INTERACTION WITH FCGR1A, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=8064233; DOI=10.1084/jem.180.3.1165;
RA   Wang A.V., Scholl P.R., Geha R.S.;
RT   "Physical and functional association of the high affinity
RT   immunoglobulin G receptor (Fc gamma RI) with the kinases Hck and
RT   Lyn.";
RL   J. Exp. Med. 180:1165-1170(1994).
RN   [9]
RP   PHOSPHORYLATION AT TYR-397 AND TYR-508, AND ENZYME REGULATION.
RX   PubMed=7935444; DOI=10.1128/MCB.14.11.7306;
RA   Hata A., Sabe H., Kurosaki T., Takata M., Hanafusa H.;
RT   "Functional analysis of Csk in signal transduction through the B-cell
RT   antigen receptor.";
RL   Mol. Cell. Biol. 14:7306-7313(1994).
RN   [10]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A.
RX   PubMed=7895172; DOI=10.1016/S1074-7613(95)80040-9;
RA   Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R.,
RA   Bolen J.B., Kieff E.;
RT   "Integral membrane protein 2 of Epstein-Barr virus regulates
RT   reactivation from latency through dominant negative effects on
RT   protein-tyrosine kinases.";
RL   Immunity 2:155-166(1995).
RN   [11]
RP   PHOSPHORYLATION AT TYR-508 BY MATK.
RC   TISSUE=Platelet;
RX   PubMed=9171348; DOI=10.1093/emboj/16.9.2342;
RA   Hirao A., Hamaguchi I., Suda T., Yamaguchi N.;
RT   "Translocation of the Csk homologous kinase (Chk/Hyl) controls
RT   activity of CD36-anchored Lyn tyrosine kinase in thrombin-stimulated
RT   platelets.";
RL   EMBO J. 16:2342-2351(1997).
RN   [12]
RP   INTERACTION WITH FCGR2B.
RX   PubMed=9232445; DOI=10.1016/S0165-2478(97)00055-2;
RA   Sarmay G., Koncz G., Pecht I., Gergely J.;
RT   "Fc gamma receptor type IIb induced recruitment of inositol and
RT   protein phosphatases to the signal transductory complex of human B-
RT   cell.";
RL   Immunol. Lett. 57:159-164(1997).
RN   [13]
RP   INTERACTION WITH KIT, AND PHOSPHORYLATION.
RX   PubMed=9341198; DOI=10.1074/jbc.272.43.27450;
RA   Linnekin D., DeBerry C.S., Mou S.;
RT   "Lyn associates with the juxtamembrane region of c-Kit and is
RT   activated by stem cell factor in hematopoietic cell lines and normal
RT   progenitor cells.";
RL   J. Biol. Chem. 272:27450-27455(1997).
RN   [14]
RP   FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF
RP   PTPN6/SHPTP1, AND INTERACTION WITH PTPN6/SHPTP1.
RX   PubMed=10574931; DOI=10.1074/jbc.274.49.34663;
RA   Yoshida K., Kharbanda S., Kufe D.;
RT   "Functional interaction between SHPTP1 and the Lyn tyrosine kinase in
RT   the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 274:34663-34668(1999).
RN   [15]
RP   INTERACTION WITH CBLC.
RX   PubMed=10362357; DOI=10.1038/sj.onc.1202753;
RA   Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M.,
RA   Penninger J., Lipkowitz S.;
RT   "cbl-3: a new mammalian cbl family protein.";
RL   Oncogene 18:3365-3375(1999).
RN   [16]
RP   FUNCTION IN CD79A PHOSPHORYLATION, AND INTERACTION WITH CD79A.
RX   PubMed=10748115; DOI=10.1074/jbc.M909044199;
RA   Gaul B.S., Harrison M.L., Geahlen R.L., Burton R.A., Post C.B.;
RT   "Substrate recognition by the Lyn protein-tyrosine kinase. NMR
RT   structure of the immunoreceptor tyrosine-based activation motif
RT   signaling region of the B cell antigen receptor.";
RL   J. Biol. Chem. 275:16174-16182(2000).
RN   [17]
RP   FUNCTION IN REGULATION OF MAST CELL PROLIFERATION, AND MUTAGENESIS OF
RP   LYS-275.
RX   PubMed=11435302; DOI=10.1182/blood.V98.2.343;
RA   O'Laughlin-Bunner B., Radosevic N., Taylor M.L., Shivakrupa R.,
RA   DeBerry C., Metcalfe D.D., Zhou M., Lowell C., Linnekin D.;
RT   "Lyn is required for normal stem cell factor-induced proliferation and
RT   chemotaxis of primary hematopoietic cells.";
RL   Blood 98:343-350(2001).
RN   [18]
RP   INTERACTION WITH PDE4A.
RC   TISSUE=Brain;
RX   PubMed=11306681;
RA   Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L.,
RA   Huston E., Sullivan M., Houslay M.D.;
RT   "Molecular cloning, genomic positioning, promoter identification, and
RT   characterization of the novel cyclic AMP-specific phosphodiesterase
RT   PDE4A10.";
RL   Mol. Pharmacol. 59:996-1011(2001).
RN   [19]
RP   FUNCTION.
RX   PubMed=10891478; DOI=10.1128/MCB.20.15.5370-5380.2000;
RA   Yoshida K., Weichselbaum R., Kharbanda S., Kufe D.;
RT   "Role for Lyn tyrosine kinase as a regulator of stress-activated
RT   protein kinase activity in response to DNA damage.";
RL   Mol. Cell. Biol. 20:5370-5380(2000).
RN   [20]
RP   FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF
RP   PPP1R15A, INTERACTION WITH PPP1R15A, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF LYS-275.
RX   PubMed=11517336; DOI=10.1073/pnas.191130798;
RA   Grishin A.V., Azhipa O., Semenov I., Corey S.J.;
RT   "Interaction between growth arrest-DNA damage protein 34 and Src
RT   kinase Lyn negatively regulates genotoxic apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10172-10177(2001).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF KIT AND DOK1, CATALYTIC ACTIVITY, AND
RP   INTERACTION WITH KIT.
RX   PubMed=11825908; DOI=10.1074/jbc.M200277200;
RA   Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B.,
RA   Resh M.D.;
RT   "Phosphatidylinositol 3-kinase and Src family kinases are required for
RT   phosphorylation and membrane recruitment of Dok-1 in c-Kit
RT   signaling.";
RL   J. Biol. Chem. 277:13732-13738(2002).
RN   [22]
RP   INTERACTION WITH MUC1.
RX   PubMed=12750561; DOI=10.4161/cbt.2.2.282;
RA   Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.;
RT   "DF3/MUC1 signaling in multiple myeloma cells is regulated by
RT   interleukin-7.";
RL   Cancer Biol. Ther. 2:187-193(2003).
RN   [23]
RP   INTERACTION WITH UNC119.
RX   PubMed=12496276; DOI=10.1074/jbc.M208261200;
RA   Cen O., Gorska M.M., Stafford S.J., Sur S., Alam R.;
RT   "Identification of UNC119 as a novel activator of SRC-type tyrosine
RT   kinases.";
RL   J. Biol. Chem. 278:8837-8845(2003).
RN   [24]
RP   FUNCTION IN THPO-MEDIATED CELL PROLIFERATION.
RX   PubMed=14726379; DOI=10.1182/blood-2003-10-3566;
RA   Lannutti B.J., Drachman J.G.;
RT   "Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of
RT   hematopoietic cell lines and primary megakaryocytic progenitors.";
RL   Blood 103:3736-3743(2004).
RN   [25]
RP   SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF LYS-275; ASP-346;
RP   GLU-353; ASP-498 AND ASP-499.
RX   PubMed=15173188; DOI=10.1083/jcb.200403011;
RA   Kasahara K., Nakayama Y., Ikeda K., Fukushima Y., Matsuda D.,
RA   Horimoto S., Yamaguchi N.;
RT   "Trafficking of Lyn through the Golgi caveolin involves the charged
RT   residues on alphaE and alphaI helices in the kinase domain.";
RL   J. Cell Biol. 165:641-652(2004).
RN   [26]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF HCLS1.
RX   PubMed=15795233; DOI=10.1074/jbc.M412634200;
RA   Brunati A.M., Deana R., Folda A., Massimino M.L., Marin O., Ledro S.,
RA   Pinna L.A., Donella-Deana A.;
RT   "Thrombin-induced tyrosine phosphorylation of HS1 in human platelets
RT   is sequentially catalyzed by Syk and Lyn tyrosine kinases and
RT   associated with the cellular migration of the protein.";
RL   J. Biol. Chem. 280:21029-21035(2005).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-508, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [29]
RP   FUNCTION.
RX   PubMed=16467205; DOI=10.1182/blood-2005-08-3343;
RA   Nakata Y., Tomkowicz B., Gewirtz A.M., Ptasznik A.;
RT   "Integrin inhibition through Lyn-dependent cross talk from CXCR4
RT   chemokine receptors in normal human CD34+ marrow cells.";
RL   Blood 107:4234-4239(2006).
RN   [30]
RP   INTERACTION WITH ABL1.
RX   PubMed=16912036; DOI=10.1074/jbc.M605902200;
RA   Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P.,
RA   Wu J., Hochrein J.M., Engen J.R., Smithgall T.E.;
RT   "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and
RT   modulate Bcr-Abl transforming activity.";
RL   J. Biol. Chem. 281:30907-30916(2006).
RN   [31]
RP   INTERACTION WITH PAG1, MUTAGENESIS OF TYR-397 AND TYR-508, ENZYME
RP   REGULATION, AND UBIQUITINATION.
RX   PubMed=16920712; DOI=10.1074/jbc.M602637200;
RA   Ingley E., Schneider J.R., Payne C.J., McCarthy D.J., Harder K.W.,
RA   Hibbs M.L., Klinken S.P.;
RT   "Csk-binding protein mediates sequential enzymatic down-regulation and
RT   degradation of Lyn in erythropoietin-stimulated cells.";
RL   J. Biol. Chem. 281:31920-31929(2006).
RN   [32]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=17233630; DOI=10.1042/BJ20061618;
RA   Rathore V.B., Okada M., Newman P.J., Newman D.K.;
RT   "Paxillin family members function as Csk-binding proteins that
RT   regulate Lyn activity in human and murine platelets.";
RL   Biochem. J. 403:275-281(2007).
RN   [33]
RP   FUNCTION IN PHOSPHORYLATION OF LPXN, AND INTERACTION WITH LPXN.
RX   PubMed=17640867; DOI=10.1074/jbc.M704625200;
RA   Chew V., Lam K.P.;
RT   "Leupaxin negatively regulates B cell receptor signaling.";
RL   J. Biol. Chem. 282:27181-27191(2007).
RN   [34]
RP   INTERACTION WITH TOM1L1, AND FUNCTION IN TOM1L1 PHOSPHORYLATION.
RX   PubMed=17977829; DOI=10.1074/jbc.M705168200;
RA   Zhang J., Suzuki K., Hitomi T., Siraganian R.P.;
RT   "TOM1L1 is a Lyn substrate involved in FcepsilonRI signaling in mast
RT   cells.";
RL   J. Biol. Chem. 282:37669-37677(2007).
RN   [35]
RP   FUNCTION IN CELL PROLIFERATION AND SURVIVAL, PHOSPHORYLATION,
RP   SUBCELLULAR LOCATION, AND ROLE IN DISEASE.
RX   PubMed=18056483; DOI=10.1182/blood-2007-04-082099;
RA   Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B.,
RA   Recher C.;
RT   "A critical role for Lyn in acute myeloid leukemia.";
RL   Blood 111:2269-2279(2008).
RN   [36]
RP   FUNCTION, PHOSPHORYLATION AT TYR-397 AND TYR-508, INTERACTION WITH
RP   PAG1 AND STAT3, AND SUBCELLULAR LOCATION.
RX   PubMed=18070987; DOI=10.1182/blood-2007-05-090985;
RA   Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D.,
RA   van Echten-Deckert G., Lindquist J.A., Schraven B., Din N.U.,
RA   Borisch B., Hoessli D.C.;
RT   "Oncogenic association of the Cbp/PAG adaptor protein with the Lyn
RT   tyrosine kinase in human B-NHL rafts.";
RL   Blood 111:2310-2320(2008).
RN   [37]
RP   INTERACTION WITH CBL AND BCR-ABL, FUNCTION IN PHOSPHORYLATION OF
RP   BCR-ABL, AND ROLE IN DISEASE.
RX   PubMed=18235045; DOI=10.1182/blood-2007-08-109330;
RA   Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M.,
RA   Donato N.J.;
RT   "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl
RT   protein stability in imatinib-resistant chronic myelogenous leukemia
RT   cells.";
RL   Blood 111:3821-3829(2008).
RN   [38]
RP   SUBCELLULAR LOCATION, MYRISTOYLATION AT GLY-2, AND MUTAGENESIS OF
RP   GLY-2; CYS-3 AND LYS-275.
RX   PubMed=18817770; DOI=10.1016/j.yexcr.2008.08.019;
RA   Ikeda K., Nakayama Y., Togashi Y., Obata Y., Kuga T., Kasahara K.,
RA   Fukumoto Y., Yamaguchi N.;
RT   "Nuclear localization of Lyn tyrosine kinase mediated by inhibition of
RT   its kinase activity.";
RL   Exp. Cell Res. 314:3392-3404(2008).
RN   [39]
RP   FUNCTION IN ADHESION AND CELL MIGRATION.
RX   PubMed=18802065; DOI=10.4049/jimmunol.181.7.4632;
RA   Malik M., Chen Y.-Y., Kienzle M.F., Tomkowicz B.E., Collman R.G.,
RA   Ptasznik A.;
RT   "Monocyte migration and LFA-1-mediated attachment to brain
RT   microvascular endothelia is regulated by SDF-1 alpha through Lyn
RT   kinase.";
RL   J. Immunol. 181:4632-4637(2008).
RN   [40]
RP   PHOSPHORYLATION AT TYR-193 AND TYR-460, AND ROLE IN DISEASE.
RX   PubMed=18577747; DOI=10.1093/jnci/djn188;
RA   Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G.,
RA   Darnay B.G., Lamothe B., Sun H., Talpaz M., Donato N.J.;
RT   "Association between imatinib-resistant BCR-ABL mutation-negative
RT   leukemia and persistent activation of LYN kinase.";
RL   J. Natl. Cancer Inst. 100:926-939(2008).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; TYR-473 AND
RP   TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [44]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [45]
RP   INTERACTION WITH ADAM15.
RX   PubMed=19718658; DOI=10.1002/jcb.22317;
RA   Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.;
RT   "Alternative splicing of ADAM15 regulates its interactions with
RT   cellular SH3 proteins.";
RL   J. Cell. Biochem. 108:877-885(2009).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; SER-228;
RP   TYR-306; TYR-316; TYR-473 AND TYR-508, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [47]
RP   FUNCTION IN PTK2B/PYK2 PHOSPHORYLATION.
RX   PubMed=20028775; DOI=10.1189/jlb.0409227;
RA   Collins M., Tremblay M., Chapman N., Curtiss M., Rothman P.B.,
RA   Houtman J.C.;
RT   "The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402
RT   and 580 occurs via a distinct mechanism than other receptor systems.";
RL   J. Leukoc. Biol. 87:691-701(2010).
RN   [48]
RP   FUNCTION IN LTR4 AND LTR6 HETERODIMERIZATION, AND INTERACTION WITH
RP   CD36.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J.,
RA   Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A.,
RA   Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-
RT   like receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [49]
RP   INTERACTION WITH NDFIP1 AND NDFIP2, AND UBIQUITINATION.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the
RT   ubiquitin ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [51]
RP   INTERACTION WITH SCIMP.
RX   PubMed=21930792; DOI=10.1128/MCB.05817-11;
RA   Draber P., Vonkova I., Stepanek O., Hrdinka M., Kucova M.,
RA   Skopcova T., Otahal P., Angelisova P., Horejsi V., Yeung M., Weiss A.,
RA   Brdicka T.;
RT   "SCIMP, a transmembrane adapter protein involved in major
RT   histocompatibility complex class II signaling.";
RL   Mol. Cell. Biol. 31:4550-4562(2011).
RN   [52]
RP   REVIEW.
RX   PubMed=15220000; DOI=10.1016/j.molimm.2004.04.010;
RA   Lowell C.A.;
RT   "Src-family kinases: rheostats of immune cell signaling.";
RL   Mol. Immunol. 41:631-643(2004).
RN   [53]
RP   REVIEW ON ROLE IN B CELLS.
RX   PubMed=15489917; DOI=10.1038/sj.onc.1208075;
RA   Gauld S.B., Cambier J.C.;
RT   "Src-family kinases in B-cell development and signaling.";
RL   Oncogene 23:8001-8006(2004).
RN   [54]
RP   REVIEW ON ROLE IN B CELLS.
RX   PubMed=15664155; DOI=10.1016/S1074-7613(04)00381-4;
RA   Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M.;
RT   "Lyn tyrosine kinase: accentuating the positive and the negative.";
RL   Immunity 22:9-18(2005).
RN   [55]
RP   REVIEW ON ROLE IN GROWTH FACTOR SIGNALING.
RX   PubMed=16801133; DOI=10.1080/08977190600581327;
RA   Hibbs M.L., Harder K.W.;
RT   "The duplicitous nature of the Lyn tyrosine kinase in growth factor
RT   signaling.";
RL   Growth Factors 24:137-149(2006).
RN   [56]
RP   REVIEW ON ROLE IN MAST CELLS.
RX   PubMed=18772004; DOI=10.1016/S0065-2776(08)00403-3;
RA   Rivera J., Fierro N.A., Olivera A., Suzuki R.;
RT   "New insights on mast cell activation via the high affinity receptor
RT   for IgE.";
RL   Adv. Immunol. 98:85-120(2008).
RN   [57]
RP   ROLE IN MYELOID CELL FUNCTION, AND SIGNALING.
RX   PubMed=19290919; DOI=10.1111/j.1600-065X.2008.00758.x;
RA   Scapini P., Pereira S., Zhang H., Lowell C.A.;
RT   "Multiple roles of Lyn kinase in myeloid cell signaling and
RT   function.";
RL   Immunol. Rev. 228:23-40(2009).
RN   [58]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [60]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [61]
RP   MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25255805; DOI=10.1038/ncomms5919;
RA   Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U.,
RA   Wright M.H., Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.;
RT   "Global profiling of co- and post-translationally N-myristoylated
RT   proteomes in human cells.";
RL   Nat. Commun. 5:4919-4919(2014).
RN   [62]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [63]
RP   STRUCTURE BY NMR OF 61-123 IN COMPLEX WITH SAIMIRIINE HERPESVIRUS 2
RP   TYROSINE KINASE INTERACTING PROTEIN.
RX   PubMed=11955060; DOI=10.1021/bi015986j;
RA   Schweimer K., Hoffmann S., Bauer F., Friedrich U., Kardinal C.,
RA   Feller S.M., Biesinger B., Sticht H.;
RT   "Structural investigation of the binding of a herpesviral protein to
RT   the SH3 domain of tyrosine kinase Lck.";
RL   Biochemistry 41:5120-5130(2002).
RN   [64]
RP   STRUCTURE BY NMR OF 61-122, AND INTERACTION WITH HERPESVIRUS TYROSINE
RP   KINASE INTERACTING PROTEIN.
RX   PubMed=16155203; DOI=10.1110/ps.051563605;
RA   Bauer F., Schweimer K., Meiselbach H., Hoffmann S., Rosch P.,
RA   Sticht H.;
RT   "Structural characterization of Lyn-SH3 domain in complex with a
RT   herpesviral protein reveals an extended recognition motif that
RT   enhances binding affinity.";
RL   Protein Sci. 14:2487-2498(2005).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-512 IN COMPLEX WITH
RP   STAUROSPORINE.
RX   PubMed=19857964; DOI=10.1016/j.bmcl.2009.10.038;
RA   Miyano N., Kinoshita T., Nakai R., Kirii Y., Yokota K., Tada T.;
RT   "Structural basis for the inhibitor recognition of human Lyn kinase
RT   domain.";
RL   Bioorg. Med. Chem. Lett. 19:6557-6560(2009).
RN   [66]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-385.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that transmits
CC       signals from cell surface receptors and plays an important role in
CC       the regulation of innate and adaptive immune responses,
CC       hematopoiesis, responses to growth factors and cytokines, integrin
CC       signaling, but also responses to DNA damage and genotoxic agents.
CC       Functions primarily as negative regulator, but can also function
CC       as activator, depending on the context. Required for the
CC       initiation of the B-cell response, but also for its down-
CC       regulation and termination. Plays an important role in the
CC       regulation of B-cell differentiation, proliferation, survival and
CC       apoptosis, and is important for immune self-tolerance. Acts
CC       downstream of several immune receptors, including the B-cell
CC       receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A,
CC       TLR2 and TLR4. Plays a role in the inflammatory response to
CC       bacterial lipopolysaccharide. Mediates the responses to cytokines
CC       and growth factors in hematopoietic progenitors, platelets,
CC       erythrocytes, and in mature myeloid cells, such as dendritic
CC       cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT,
CC       MPL, the chemokine receptor CXCR4, as well as the receptors for
CC       IL3, IL5 and CSF2. Plays an important role in integrin signaling.
CC       Regulates cell proliferation, survival, differentiation,
CC       migration, adhesion, degranulation, and cytokine release. Down-
CC       regulates signaling pathways by phosphorylation of immunoreceptor
CC       tyrosine-based inhibitory motifs (ITIM), that then serve as
CC       binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2
CC       and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of
CC       kinases and their substrates. Phosphorylates LIME1 in response to
CC       CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A,
CC       CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B,
CC       PTK2B/PYK2, SYK and TEC. Promotes phosphorylation of SIRPA,
CC       PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates
CC       phosphorylation of the BCR-ABL fusion protein. Required for rapid
CC       phosphorylation of FER in response to FCER1 activation. Mediates
CC       KIT phosphorylation. Acts as an effector of EPOR (erythropoietin
CC       receptor) in controlling KIT expression and may play a role in
CC       erythroid differentiation during the switch between proliferation
CC       and maturation. Depending on the context, activates or inhibits
CC       several signaling cascades. Regulates phosphatidylinositol 3-
CC       kinase activity and AKT1 activation. Regulates activation of the
CC       MAP kinase signaling cascade, including activation of MAP2K1/MEK1,
CC       MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates
CC       activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-
CC       72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and
CC       signal initiation. {ECO:0000269|PubMed:10574931,
CC       ECO:0000269|PubMed:10748115, ECO:0000269|PubMed:10891478,
CC       ECO:0000269|PubMed:11435302, ECO:0000269|PubMed:11517336,
CC       ECO:0000269|PubMed:11825908, ECO:0000269|PubMed:14726379,
CC       ECO:0000269|PubMed:15795233, ECO:0000269|PubMed:16467205,
CC       ECO:0000269|PubMed:17640867, ECO:0000269|PubMed:17977829,
CC       ECO:0000269|PubMed:18056483, ECO:0000269|PubMed:18070987,
CC       ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:18577747,
CC       ECO:0000269|PubMed:18802065, ECO:0000269|PubMed:19290919,
CC       ECO:0000269|PubMed:20028775, ECO:0000269|PubMed:20037584,
CC       ECO:0000269|PubMed:7687428}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11517336,
CC       ECO:0000269|PubMed:11825908, ECO:0000269|PubMed:7682714,
CC       ECO:0000269|PubMed:8064233}.
CC   -!- ENZYME REGULATION: Subject to autoinhibition, mediated by
CC       intramolecular interactions between the SH2 domain and the C-
CC       terminal phosphotyrosine. Phosphorylation at Tyr-397 is required
CC       for optimal activity. Phosphorylated by CSK at Tyr-508;
CC       phosphorylation at Tyr-508 inhibits kinase activity. Kinase
CC       activity is modulated by dephosphorylation by PTPRC/CD45.
CC       Inhibited by Dasatinib, PP2, and SU6656.
CC       {ECO:0000269|PubMed:16920712, ECO:0000269|PubMed:7935444}.
CC   -!- SUBUNIT: Interacts with TEC. Interacts (via SH2 domain) with FLT3
CC       (tyrosine phosphorylated). Interacts with LIME1 and with CD79A
CC       upon activation of the B-cell antigen receptor. Interacts with the
CC       B-cell receptor complex. Interacts with phosphorylated THEMIS2.
CC       Interacts with EPOR. Interacts with MS4A2/FCER1B. Interaction (via
CC       the SH2 and SH3 domains) with MUC1 is stimulated by IL7 and the
CC       subsequent phosphorylation increases the binding between MUC1 and
CC       CTNNB1/beta-catenin. Interacts with ADAM15. Interacts with NDFIP2
CC       and more weakly with NDFIP1. Interacts with FASLG. Interacts with
CC       KIT. Interacts with HCLS1. Interacts with FCGR2B. Interacts with
CC       FCGR1A; the interaction may be indirect. Interacts with CD19,
CC       CD22, CD79A and CD79B. Interacts (via SH3 domain) with CBLC,
CC       PPP1R15A and PDE4A. Interacts with TGFB1I1. Interacts (via SH3
CC       domain) with PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase; this interaction enhances
CC       phosphatidylinositol 3-kinase activity. Interacts with CSF2RB, the
CC       common subunit of the IL3, IL5 and CSF2 receptors. Interacts with
CC       PAG1; identified in a complex with PAG1 and STAT3. Interacts with
CC       ABL1. Interacts with PTPN6/SHP-1. Interacts (via SH3 domain) with
CC       SCIMP (via proline-rich region). Interacts with LPXN (via LD motif
CC       3) and the interaction is induced upon B-cell antigen receptor
CC       (BCR) activation. Interacts (via SH3-domain) with ANKRD54 (via
CC       ankyrin repeat region) in an activation-independent status of LYN.
CC       Forms a multiprotein complex with ANKRD54 and HCLS1. Interacts
CC       with Epstein-Barr virus LMP2A. Interacts with Herpes virus saimiri
CC       tyrosine kinase interacting protein (Tip). Interacts (via SH2 and
CC       SH3 domains) with UNC119; leading to LYN activation. Interacts
CC       with CD36. Interacts with LYN (By similarity).
CC       {ECO:0000250|UniProtKB:P25911, ECO:0000269|PubMed:10362357,
CC       ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:10748115,
CC       ECO:0000269|PubMed:11306681, ECO:0000269|PubMed:11517336,
CC       ECO:0000269|PubMed:11825908, ECO:0000269|PubMed:11955060,
CC       ECO:0000269|PubMed:12496276, ECO:0000269|PubMed:12750561,
CC       ECO:0000269|PubMed:16155203, ECO:0000269|PubMed:16912036,
CC       ECO:0000269|PubMed:16920712, ECO:0000269|PubMed:17233630,
CC       ECO:0000269|PubMed:17640867, ECO:0000269|PubMed:17977829,
CC       ECO:0000269|PubMed:18070987, ECO:0000269|PubMed:18235045,
CC       ECO:0000269|PubMed:19718658, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:19857964, ECO:0000269|PubMed:20037584,
CC       ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:21930792,
CC       ECO:0000269|PubMed:7682714, ECO:0000269|PubMed:7687428,
CC       ECO:0000269|PubMed:7895172, ECO:0000269|PubMed:8064233,
CC       ECO:0000269|PubMed:9232445, ECO:0000269|PubMed:9341198}.
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-79452, EBI-710506;
CC       P22575:- (xeno); NbExp=3; IntAct=EBI-79452, EBI-866709;
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-79452, EBI-706378;
CC       Q9WMX2:- (xeno); NbExp=3; IntAct=EBI-79452, EBI-710918;
CC       P10275:AR; NbExp=5; IntAct=EBI-79452, EBI-608057;
CC       Q8R5G7:Arap3 (xeno); NbExp=2; IntAct=EBI-79452, EBI-621463;
CC       P20273:CD22; NbExp=2; IntAct=EBI-79452, EBI-78277;
CC       P25063:CD24; NbExp=6; IntAct=EBI-79452, EBI-6267018;
CC       P11049:CD37; NbExp=5; IntAct=EBI-79452, EBI-6139068;
CC       P46527:CDKN1B; NbExp=2; IntAct=EBI-79452, EBI-519280;
CC       P00533:EGFR; NbExp=6; IntAct=EBI-79452, EBI-297353;
CC       Q13480:GAB1; NbExp=7; IntAct=EBI-79452, EBI-517684;
CC       Q9HCN6:GP6; NbExp=2; IntAct=EBI-79452, EBI-515278;
CC       P05556:ITGB1; NbExp=4; IntAct=EBI-79452, EBI-703066;
CC       P10721:KIT; NbExp=7; IntAct=EBI-79452, EBI-1379503;
CC       P33993:MCM7; NbExp=5; IntAct=EBI-6895930, EBI-355924;
CC       P08581:MET; NbExp=2; IntAct=EBI-79452, EBI-1039152;
CC       Q9NWQ8:PAG1; NbExp=16; IntAct=EBI-79452, EBI-2828115;
CC       P63244:RACK1; NbExp=2; IntAct=EBI-79452, EBI-296739;
CC       P12931:SRC; NbExp=2; IntAct=EBI-79452, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Nucleus. Cytoplasm.
CC       Cytoplasm, perinuclear region. Golgi apparatus. Membrane
CC       {ECO:0000305}; Lipid-anchor {ECO:0000305}. Note=Accumulates in the
CC       nucleus by inhibition of CRM1-mediated nuclear export. Nuclear
CC       accumulation is increased by inhibition of its kinase activity.
CC       The trafficking from the Golgi apparatus to the plasma membrane
CC       occurs in a kinase domain-dependent but kinase activity
CC       independent manner and is mediated by exocytic vesicular
CC       transport. Detected on plasma membrane lipid rafts.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=LYN A, p56lyn;
CC         IsoId=P07948-1; Sequence=Displayed;
CC       Name=2; Synonyms=LYN B, p53lyn;
CC         IsoId=P07948-2; Sequence=VSP_005002;
CC   -!- TISSUE SPECIFICITY: Detected in monocytes (at protein level).
CC       Detected in placenta, and in fetal brain, lung, liver and kidney.
CC       Widely expressed in a variety of organs, tissues, and cell types
CC       such as epidermoid, hematopoietic, and neuronal cells. Expressed
CC       in primary neuroblastoma tumors. {ECO:0000269|PubMed:3561390,
CC       ECO:0000269|PubMed:8064233}.
CC   -!- DOMAIN: The protein kinase domain plays an important role in its
CC       localization in the cell membrane. {ECO:0000269|PubMed:15173188}.
CC   -!- PTM: Ubiquitinated by CBL, leading to its degradation.
CC       Ubiquitination is SH3-dependent. {ECO:0000269|PubMed:16920712,
CC       ECO:0000269|PubMed:20534535}.
CC   -!- PTM: Autophosphorylated. Phosphorylated on tyrosine residues in
CC       response to KIT signaling. Phosphorylation at Tyr-397 is required
CC       for optimal activity. Phosphorylation at Tyr-508 inhibits kinase
CC       activity. Phosphorylated at Tyr-508 by CSK. Dephosphorylated by
CC       PTPRC/CD45. Becomes rapidly phosphorylated upon activation of the
CC       B-cell receptor and the immunoglobulin receptor FCGR1A.
CC       {ECO:0000269|PubMed:18056483, ECO:0000269|PubMed:18070987,
CC       ECO:0000269|PubMed:18577747, ECO:0000269|PubMed:7935444,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:9171348,
CC       ECO:0000269|PubMed:9341198}.
CC   -!- DISEASE: Note=Constitutively phosphorylated and activated in cells
CC       from a number of chronic myelogenous leukemia (CML) and acute
CC       myeloid leukemia (AML) patients. Mediates phosphorylation of the
CC       BCR-ABL fusion protein. Abnormally elevated expression levels or
CC       activation of LYN signaling may play a role in survival and
CC       proliferation of some types of cancer cells.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16038; AAA59540.1; -; mRNA.
DR   EMBL; M79321; AAB50019.1; -; mRNA.
DR   EMBL; BC075001; AAH75001.1; -; mRNA.
DR   EMBL; BC075002; AAH75002.1; -; mRNA.
DR   EMBL; BC126456; AAI26457.1; -; mRNA.
DR   EMBL; BC126458; AAI26459.1; -; mRNA.
DR   CCDS; CCDS47859.1; -. [P07948-2]
DR   CCDS; CCDS6162.1; -. [P07948-1]
DR   PIR; A26719; TVHULY.
DR   RefSeq; NP_001104567.1; NM_001111097.2. [P07948-2]
DR   RefSeq; NP_002341.1; NM_002350.3. [P07948-1]
DR   RefSeq; XP_016868905.1; XM_017013416.1. [P07948-2]
DR   UniGene; Hs.491767; -.
DR   UniGene; Hs.545418; -.
DR   PDB; 1W1F; NMR; -; A=61-123.
DR   PDB; 1WA7; NMR; -; A=61-123.
DR   PDB; 3A4O; X-ray; 3.00 A; X=233-512.
DR   PDBsum; 1W1F; -.
DR   PDBsum; 1WA7; -.
DR   PDBsum; 3A4O; -.
DR   ProteinModelPortal; P07948; -.
DR   SMR; P07948; -.
DR   BioGrid; 110245; 191.
DR   DIP; DIP-1056N; -.
DR   IntAct; P07948; 70.
DR   MINT; MINT-200655; -.
DR   STRING; 9606.ENSP00000428924; -.
DR   BindingDB; P07948; -.
DR   ChEMBL; CHEMBL3905; -.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB08901; Ponatinib.
DR   GuidetoPHARMACOLOGY; 2060; -.
DR   iPTMnet; P07948; -.
DR   PhosphoSitePlus; P07948; -.
DR   SwissPalm; P07948; -.
DR   BioMuta; LYN; -.
DR   DMDM; 125480; -.
DR   REPRODUCTION-2DPAGE; P07948; -.
DR   EPD; P07948; -.
DR   MaxQB; P07948; -.
DR   PaxDb; P07948; -.
DR   PeptideAtlas; P07948; -.
DR   PRIDE; P07948; -.
DR   DNASU; 4067; -.
DR   Ensembl; ENST00000519728; ENSP00000428924; ENSG00000254087. [P07948-1]
DR   Ensembl; ENST00000520220; ENSP00000428424; ENSG00000254087. [P07948-2]
DR   GeneID; 4067; -.
DR   KEGG; hsa:4067; -.
DR   UCSC; uc003xsk.5; human. [P07948-1]
DR   CTD; 4067; -.
DR   DisGeNET; 4067; -.
DR   GeneCards; LYN; -.
DR   HGNC; HGNC:6735; LYN.
DR   HPA; CAB004492; -.
DR   HPA; HPA001231; -.
DR   MIM; 165120; gene.
DR   neXtProt; NX_P07948; -.
DR   OpenTargets; ENSG00000254087; -.
DR   PharmGKB; PA30498; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P07948; -.
DR   KO; K05854; -.
DR   OMA; WWRAKSL; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; P07948; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2454202; Fc epsilon receptor (FCERI) signaling.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-5621480; Dectin-2 family.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5690714; CD22 mediated BCR regulation.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P07948; -.
DR   SIGNOR; P07948; -.
DR   ChiTaRS; LYN; human.
DR   EvolutionaryTrace; P07948; -.
DR   GeneWiki; LYN; -.
DR   GenomeRNAi; 4067; -.
DR   PMAP-CutDB; P07948; -.
DR   PRO; PR:P07948; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000254087; -.
DR   CleanEx; HS_LYN; -.
DR   ExpressionAtlas; P07948; baseline and differential.
DR   Genevisible; P07948; HS.
DR   GO; GO:0005913; C:cell-cell adherens junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0034666; C:integrin alpha2-beta1 complex; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0030061; C:mitochondrial crista; IEA:Ensembl.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0043015; F:gamma-tubulin binding; IEA:Ensembl.
DR   GO; GO:0043208; F:glycosphingolipid binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IEA:Ensembl.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0051219; F:phosphoprotein binding; IEA:Ensembl.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:Ensembl.
DR   GO; GO:0004716; F:signal transducer, downstream of receptor, with protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001782; P:B cell homeostasis; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0050663; P:cytokine secretion; IEA:Ensembl.
DR   GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0002774; P:Fc receptor mediated inhibitory signaling pathway; ISS:UniProtKB.
DR   GO; GO:0002431; P:Fc receptor mediated stimulatory signaling pathway; ISS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0002768; P:immune response-regulating cell surface receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IBA:GO_Central.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0050777; P:negative regulation of immune response; TAS:UniProtKB.
DR   GO; GO:1902532; P:negative regulation of intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0070667; P:negative regulation of mast cell proliferation; ISS:UniProtKB.
DR   GO; GO:0002762; P:negative regulation of myeloid leukocyte differentiation; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; ISS:UniProtKB.
DR   GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; IDA:UniProtKB.
DR   GO; GO:2000670; P:positive regulation of dendritic cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0060369; P:positive regulation of Fc receptor mediated stimulatory signaling pathway; IEA:Ensembl.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070668; P:positive regulation of mast cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0070447; P:positive regulation of oligodendrocyte progenitor proliferation; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IEA:Ensembl.
DR   GO; GO:0070304; P:positive regulation of stress-activated protein kinase signaling cascade; IDA:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; IBA:GO_Central.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IMP:UniProtKB.
DR   GO; GO:0001817; P:regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0050707; P:regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045646; P:regulation of erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0033003; P:regulation of mast cell activation; ISS:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; ISS:UniProtKB.
DR   GO; GO:0090025; P:regulation of monocyte chemotaxis; IMP:UniProtKB.
DR   GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; TAS:UniProtKB.
DR   GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0009725; P:response to hormone; ISS:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0006991; P:response to sterol depletion; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0002513; P:tolerance induction to self antigen; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IMP:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Golgi apparatus;
KW   Host-virus interaction; Immunity; Inflammatory response;
KW   Innate immunity; Kinase; Lipoprotein; Membrane; Myristate;
KW   Nucleotide-binding; Nucleus; Palmitate; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:25255805}.
FT   CHAIN         2    512       Tyrosine-protein kinase Lyn.
FT                                /FTId=PRO_0000088129.
FT   DOMAIN       63    123       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      129    226       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      247    501       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     253    261       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    367    367       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     275    275       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      11     11       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     193    193       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18577747}.
FT   MOD_RES     228    228       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     306    306       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     316    316       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     397    397       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18070987,
FT                                ECO:0000269|PubMed:7935444}.
FT   MOD_RES     460    460       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18577747}.
FT   MOD_RES     473    473       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     508    508       Phosphotyrosine; by autocatalysis, CSK
FT                                and MATK. {ECO:0000244|PubMed:15592455,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:18070987,
FT                                ECO:0000269|PubMed:7935444,
FT                                ECO:0000269|PubMed:9171348}.
FT   LIPID         2      2       N-myristoyl glycine.
FT                                {ECO:0000269|PubMed:25255805,
FT                                ECO:0000305|PubMed:18817770}.
FT   LIPID         3      3       S-palmitoyl cysteine. {ECO:0000305}.
FT   VAR_SEQ      23     43       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8125304}.
FT                                /FTId=VSP_005002.
FT   VARIANT     385    385       D -> Y (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041737.
FT   MUTAGEN       2      2       G->A: Loss of localization to the cell
FT                                membrane; when associated with A-3.
FT                                {ECO:0000269|PubMed:18817770}.
FT   MUTAGEN       3      3       C->A: Loss of localization to the cell
FT                                membrane; when associated with A-2.
FT                                {ECO:0000269|PubMed:18817770}.
FT   MUTAGEN     275    275       K->A: Loss of activity and no effect on
FT                                localization to the cell membrane.
FT                                Abundant localization in the nucleus;
FT                                when associated with A-2 and A-3.
FT                                {ECO:0000269|PubMed:11435302,
FT                                ECO:0000269|PubMed:11517336,
FT                                ECO:0000269|PubMed:15173188,
FT                                ECO:0000269|PubMed:18817770}.
FT   MUTAGEN     275    275       K->L,R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11435302,
FT                                ECO:0000269|PubMed:11517336,
FT                                ECO:0000269|PubMed:15173188,
FT                                ECO:0000269|PubMed:18817770}.
FT   MUTAGEN     346    346       D->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-353; A-498 and A-
FT                                499. {ECO:0000269|PubMed:15173188}.
FT   MUTAGEN     353    353       E->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-346; A-498 and A-
FT                                499. {ECO:0000269|PubMed:15173188}.
FT   MUTAGEN     397    397       Y->F: Strongly reduced kinase activity.
FT                                {ECO:0000269|PubMed:16920712}.
FT   MUTAGEN     498    498       D->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-346; A-353 and A-
FT                                499. {ECO:0000269|PubMed:15173188}.
FT   MUTAGEN     499    499       D->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-346; A-353 and A-
FT                                498. {ECO:0000269|PubMed:15173188}.
FT   MUTAGEN     508    508       Y->F: Abolishes autoinhibition and
FT                                thereby increases kinase activity.
FT                                {ECO:0000269|PubMed:16920712}.
FT   STRAND       66     72       {ECO:0000244|PDB:1W1F}.
FT   STRAND       78     80       {ECO:0000244|PDB:1W1F}.
FT   STRAND       89     95       {ECO:0000244|PDB:1W1F}.
FT   STRAND       97    104       {ECO:0000244|PDB:1W1F}.
FT   TURN        105    107       {ECO:0000244|PDB:1W1F}.
FT   STRAND      110    114       {ECO:0000244|PDB:1W1F}.
FT   TURN        115    117       {ECO:0000244|PDB:1W1F}.
FT   STRAND      118    120       {ECO:0000244|PDB:1W1F}.
FT   STRAND      259    262       {ECO:0000244|PDB:3A4O}.
FT   STRAND      265    269       {ECO:0000244|PDB:3A4O}.
FT   STRAND      273    275       {ECO:0000244|PDB:3A4O}.
FT   STRAND      284    286       {ECO:0000244|PDB:3A4O}.
FT   TURN        287    289       {ECO:0000244|PDB:3A4O}.
FT   HELIX       290    293       {ECO:0000244|PDB:3A4O}.
FT   TURN        294    297       {ECO:0000244|PDB:3A4O}.
FT   STRAND      306    309       {ECO:0000244|PDB:3A4O}.
FT   STRAND      311    314       {ECO:0000244|PDB:3A4O}.
FT   STRAND      316    319       {ECO:0000244|PDB:3A4O}.
FT   HELIX       327    330       {ECO:0000244|PDB:3A4O}.
FT   HELIX       334    338       {ECO:0000244|PDB:3A4O}.
FT   HELIX       341    360       {ECO:0000244|PDB:3A4O}.
FT   STRAND      372    375       {ECO:0000244|PDB:3A4O}.
FT   STRAND      381    383       {ECO:0000244|PDB:3A4O}.
FT   HELIX       407    409       {ECO:0000244|PDB:3A4O}.
FT   HELIX       412    416       {ECO:0000244|PDB:3A4O}.
FT   HELIX       422    437       {ECO:0000244|PDB:3A4O}.
FT   TURN        449    451       {ECO:0000244|PDB:3A4O}.
FT   HELIX       452    457       {ECO:0000244|PDB:3A4O}.
FT   STRAND      466    468       {ECO:0000244|PDB:3A4O}.
FT   HELIX       470    477       {ECO:0000244|PDB:3A4O}.
FT   TURN        478    480       {ECO:0000244|PDB:3A4O}.
FT   TURN        484    486       {ECO:0000244|PDB:3A4O}.
FT   HELIX       490    502       {ECO:0000244|PDB:3A4O}.
SQ   SEQUENCE   512 AA;  58574 MW;  408D3D461204E378 CRC64;
     MGCIKSKGKD SLSDDGVDLK TQPVRNTERT IYVRDPTSNK QQRPVPESQL LPGQRFQTKD
     PEEQGDIVVA LYPYDGIHPD DLSFKKGEKM KVLEEHGEWW KAKSLLTKKE GFIPSNYVAK
     LNTLETEEWF FKDITRKDAE RQLLAPGNSA GAFLIRESET LKGSFSLSVR DFDPVHGDVI
     KHYKIRSLDN GGYYISPRIT FPCISDMIKH YQKQADGLCR RLEKACISPK PQKPWDKDAW
     EIPRESIKLV KRLGAGQFGE VWMGYYNNST KVAVKTLKPG TMSVQAFLEE ANLMKTLQHD
     KLVRLYAVVT REEPIYIITE YMAKGSLLDF LKSDEGGKVL LPKLIDFSAQ IAEGMAYIER
     KNYIHRDLRA ANVLVSESLM CKIADFGLAR VIEDNEYTAR EGAKFPIKWT APEAINFGCF
     TIKSDVWSFG ILLYEIVTYG KIPYPGRTNA DVMTALSQGY RMPRVENCPD ELYDIMKMCW
     KEKAEERPTF DYLQSVLDDF YTATEGQYQQ QP
//
